IL-13 is known to play a key role in the pathogenesis of asthma, and its upregulation has been associated with increased levels of CCL13 in the serum of asthma patients; Using Lebrikizumab, a monoclonal antibody that blocks the IL-13Rα1/IL-4Rα receptors, has had good results in lowering the serum concentrations of CCL17, CCL13, and total IgE in asthma patients (16). This evidence concerns the gene IL13RA1 and asthma.